5,452 Shares in Humana Inc. (NYSE:HUM) Acquired by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in Humana Inc. (NYSE:HUM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,452 shares of the insurance provider’s stock, valued at approximately $1,727,000.

Other large investors have also recently bought and sold shares of the company. Creative Financial Designs Inc. ADV boosted its stake in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the period. CarsonAllaria Wealth Management Ltd. boosted its position in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the last quarter. Atwood & Palmer Inc. bought a new stake in shares of Humana during the 3rd quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new position in shares of Humana during the third quarter worth about $31,000. Finally, Your Advocates Ltd. LLP increased its holdings in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Trading Down 0.5 %

Shares of NYSE HUM opened at $281.73 on Friday. The stock has a market cap of $33.92 billion, a P/E ratio of 24.95, a price-to-earnings-growth ratio of 2.27 and a beta of 0.53. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $488.89. The firm has a 50-day moving average of $272.68 and a 200 day moving average of $327.04.

Humana (NYSE:HUM) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, sell-side analysts expect that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is 31.36%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Sanford C. Bernstein upgraded Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a report on Tuesday, October 8th. Barclays lifted their price target on shares of Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Leerink Partners cut shares of Humana from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Wells Fargo & Company lowered their target price on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and upped their price target for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Twenty research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.